Global Neurohealth Ventures

The firm does not publicly disclose its investment committee or managing partners. Based on its structure as a private equity firm, decisions are likely made by a small team of general partners, though individual names are not available in public sources.

The firm likely leverages relationships within academic neuroscience centers, medical schools, and neurotech accelerators. Its narrow focus on neurohealth may provide access to pre-commercial technologies that generalist funds overlook, though specific sourcing methods are not publicly documented.

The firm identifies as an asset manager and private equity firm, which suggests a fund-based structure typical of venture capital. However, the lack of public AUM or vehicle details leaves the exact legal structure unconfirmed — it could operate as a fund, a family office, or a combination.

Public sources indicate the firm makes direct investments in early-stage neurohealth companies, primarily at seed and Series A. There is no evidence of fund-of-funds or secondary commitments, but the firm's full mandate is not publicly detailed.

The firm targets early-stage venture rounds, specifically seed and Series A. Its focus on neurohealth startups with long development timelines suggests comfort with pre-revenue, research-stage companies that require significant technical diligence.